UK AAV Gene Therapy Market Analysis, 2024–2034

The UK AAV Gene Therapy Market Analysis Executive Summary

AAV gene therapies use harmless adeno-associated viruses to deliver working genes into cells, often as a one-time treatment.

Key segments of the AAV Gene Therapy market include indication (Neuromuscular Diseases, Hemophilia and Eye Diseases) and route (Intravenous, Subretinal and Intrathecal).

UK AAV Gene Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the AAV Gene Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the AAV Gene Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the AAV Gene Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for AAV Gene Therapy Market in UK

The AAV Gene Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

• Novartis
• SSarepta Therapeutics
• BBioMarin
• CCSL Behring
• UUltragenyx
• RREGENXBIO

Healthcare Policies and Regulatory Landscape for AAV Gene Therapy Market in UK

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AAV Gene Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.

1. 1 Market Analysis

   • 1.1 Research Scope and Assumption
   • 1.2 Objective of the study
   • 1.3 Research Methodology
   • 1.4 Reason to buy the report

2. 2 Market Analysis Executive Summary

   • 2.1 Market Analysis - Industry Snapshot & key buying criteria, 2025-2034
   • 2.2 Market Size, Growth Prospects and Key findings

3. 3 Market Dynamics

   • 3.1 Market Growth Drivers Analysis
   • 3.2 Market Restraints Analysis

4. 4 Market Segmentation

   • 4.1 By Indication
   • 4.2 By Route
   • 4.3 By End User

5. 5 By Market Share

   • 5.1 Market Analysis, Insights and Forecast – By Revenue

6. 6 Competitive Landscape

   • 6.1 Major Top Market Players Products in Pipeline
   • 6.2 R&D Initiatives
   • 6.3 Notable recent Deals
   • 6.3.1 Strategic Divestments
   • 6.3.2 Mergers & Acquisitions
   • 6.3.3 Partnerships
   • 6.3.4 Joint Ventures

7. 7 Key Company Profiles

   • 7.1 Novartis
   • 7.2 Sarepta Therapeutics
   • 7.3 BioMarin
   • 7.4 CSL Behring
   • 7.5 Ultragenyx
   • 7.6 REGENXBIO

8. 8 Healthcare Policies and Regulatory Landscape

   • 8.1 Policy changes and Reimbursement scenario
   • 8.2 Government Initiatives / Intervention programs

The AAV Gene Therapy market can be segmented based on various criteria, including indication, route and end user. Here's a breakdown of the market segmentation